Angiœdèmes héréditaires sur ­déficit en C1-inhibiteur : nouveautés ­thérapeutiques [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches]

Details

Serval ID
serval:BIB_5093AD198998
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Angiœdèmes héréditaires sur ­déficit en C1-inhibiteur : nouveautés ­thérapeutiques [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches]
Journal
Revue medicale suisse
Author(s)
Stehlin F., Ribi C.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
08/04/2020
Peer-reviewed
Oui
Volume
16
Number
689
Pages
675-678
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Hereditary angioedema type 1 and 2 are due to a deficiency in C1--esterase inhibitor. This molecule inhibits the generation of bradykinin, a potent inflammatory mediator that increases vascular permeability. Upon accumulation of bradykinin, patients affected develop painful subcutaneous or submucosal edemas that last for several days. In case the upper airways are affected, there is risk of suffocation. This type of angioedema does not respond to antihistamines, cortico-steroids or epinephrine. Management of angioedema attacks consists in injecting C1-esterase inhibitor concentrate or icatibant, a bradykinin receptor B2 antagonist. Preventive measures aim at reducing the frequency and the severity of angioedema attacks. Inhibition of -plasma kallikrein by lanadelumab, a monoclonal antibody adminis-tered subcutaneously, is effective and well tolerated.
Keywords
Angioedema, Angioedemas, Hereditary/drug therapy, Angioedemas, Hereditary/enzymology, Antibodies, Monoclonal, Bradykinin/analogs & derivatives, Bradykinin/therapeutic use, Complement C1 Inhibitor Protein/therapeutic use, Complement Inactivating Agents/therapeutic use, Esterases/antagonists & inhibitors, Humans
Pubmed
Create date
25/04/2020 21:44
Last modification date
03/07/2020 6:26
Usage data